XR 368

Drug Profile

XR 368

Latest Information Update: 01 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenova Group
  • Class Antiepileptic drugs; Anxiolytics; Neuroprotectants
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Epilepsy

Most Recent Events

  • 01 Aug 2002 Discontinued - Preclinical for Anxiety disorders in United Kingdom (unspecified route)
  • 01 Aug 2002 Discontinued - Preclinical for Epilepsy in United Kingdom (unspecified route)
  • 31 Jul 2001 No-Development-Reported for Anxiety disorders in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top